|Day Low/High||20.02 / 20.76|
|52 Wk Low/High||16.56 / 62.70|
Its stock will be linked to Exubera's poor launch, at least until some of its other drugs hit the market.
Biotech and pharmaceutical stocks were flat, even with Hologic's $6.2 billion deal for Cytyc.
The company's alcohol-treatment drug did not have the expected impact.
Cramer admits to being wrong on the biopharmaceutical company.
Cramer says mea culpa about not being an NYSE fan and also gets a kick out of the Giants' Jay Feely.
Cramer prefers McDonald's to the Mexican fast-food outfit.
The inhaled insulin will go on sale in September, a few weeks later than planned.
Pfizer and Nektar will know soon enough if diabetics are ready to make the switch from injections to inhaled insulin.
The cost of the inhaled insulin Exubera hasn't been disclosed, but the drug hits the market in July.
The drugmaker says two studies show that diabetics will prefer inhaled insulin to injections.
The drugmaker has yet to announce a price for the treatment, which it touts as more convenient than injectable insulin.
This year's ADA meeting is set to showcase new and upcoming treatment options.
The drug safety stock just hit a 52-week high but could see another boost soon. Cramer explans why.
Cramer offers his take on Matria, Healthways, Amylin and Nektar Therapeutics in the diabetic sector. Plus, UnitedHealth's CEO gets grilled on options.
Alliances with big pharma are key for boosting smaller companies' profiles.
Misonix soars 57% after the FDA clears its product for removing soft tissue legions in surgeries.
Sign up to get started or log in to see your watchlist.
Enter a symbol above to add it to your watchlist.
A confirmation email has been sent to the address provided during registration. Please click on the appropriate link to confirm your email address.